Piper Sandler and H.C. Wainwright Stay Bullish on CytomX (CTMX)

Core Viewpoint - CytomX Therapeutics, Inc. (NASDAQ:CTMX) is gaining attention as a promising investment opportunity, particularly as it approaches significant clinical data readouts for its CX-2051 therapy in colorectal cancer, with bullish ratings from Piper Sandler and H.C. Wainwright [1][2][3] Group 1: Analyst Ratings and Price Targets - Piper Sandler reaffirmed a Buy rating on CytomX with a price target of $6.50 [1] - H.C. Wainwright reiterated a Buy rating with a higher price target of $10, indicating strong confidence in the company's upcoming data [2] Group 2: Performance Benchmarks for CX-2051 - H.C. Wainwright outlined optimistic performance benchmarks for CX-2051, expecting an objective response rate of 25% to 30% or higher, median progression-free survival of at least six months, and Grade 3 diarrhea in less than 5% of patients in a "slam dunk" scenario [2][3] - A "bull case" scenario includes an objective response rate of 15% to 20% or higher, median progression-free survival of at least five months, and Grade 3 diarrhea in less than 10% of patients [3] Group 3: Bear Case Scenario - The "bear case" scenario defined by H.C. Wainwright includes an objective response rate of 10% or lower and median progression-free survival of only two to three months, providing investors with clear metrics to assess the upcoming clinical results [4] Group 4: Company Overview - CytomX Therapeutics is a clinical-stage biopharmaceutical company focused on developing masked biologics that conditionally activate in the tumor microenvironment, emphasizing its oncology focus [4]